Peroxisome proliferator-activated receptor-γ agonists prevent tumor necrosis factor-α-mediated inhibition of FSH-induced follicle development and estradiol production in a preantral follicle culture system

Journal of Mammalian Ova Research

Volumn 31, Issue 1, 2014, Pages 2-11

  Hara, Shuichiro ^a,b   Takahashi, Toshifumi ^a   Igarashi, Hideki ^a   Amita, Mitsuyoshi ^a   Matsuo, Koki ^a   Hasegawa, Ayumi ^a   Kurachi, Hirohisa ^a  

^a YAMAGATA UNIVERSITY   (Japan)

^b Utsunomiya Hospital   (Japan)

Author keywords

Bezafibrate; Pioglitazone; Polycystic ovary syndrome; PPAR ; TNF

Indexed keywords

EID: 84902179568     PISSN: 13417738     EISSN: 13475878     Source Type: Journal    
DOI: 10.1274/jmor.31.2     Document Type: Conference Paper

References (46)

1. Asunción, M., Calvo, R. M., San Millan, J. L., Sancho, J., Avila, S. and Escobar-Morreale, H. F. (2000): A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab. 85, 2434-2438. [Medline] (Pubitemid 32269197)
2. ACOG Committee on Practice Bulletins - Gynecology. (2009): ACOG Practice Bulletin No. 108: Polycystic ovary syndrome. Obstet Gynecol. 114, 936-949. [Medline] [CrossRef]
3. DeUgarte, C. M., Bartolucci, A. A. and Azziz, R. (2005): Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril. 83, 1454-1460. [Medline] [CrossRef] (Pubitemid 40615820)
4. Adashi, E. Y., Resnick, C. E., D'Ercole, A. J., Svoboda, M. E. and Van Wyk, J. J. (1985): Insulin-like growth factors as intraovarian regulators of granulosa cell growth and function. Endocr Rev. 6, 400-420. [Medline] [CrossRef]
5. Nestler, J. E., Powers, L. P., Matt, D. W., Steingold, K. A., Plymate, S. R., Rittmaster, R. S., Clore, J. N. and Blackard, W. G. (1991): A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 72, 83-89. [Medline] [CrossRef] (Pubitemid 21921660)
6. Palomba, S., Falbo, A., Zullo, F. and Orio, F., Jr. (2009): Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr Rev. 30, 1-50. [Medline] [CrossRef]
7. Diamanti-Kandarakis, E. and Dunaif, A. (2012): Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 33, 981-1030. [Medline] [CrossRef]
8. Moll, E., Bossuyt, P. M., Korevaar, J. C., Lambalk, C. B. and van der Veen, F. (2006): Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ. 332, 1485. [Medline] [CrossRef]
9. Palomba, S., Orio, F., Jr., Falbo, A., Russo, T., Tolino, A. and Zullo, F. (2007): Clomiphene citrate versus metformin as first-line approach for the treatment of anovulation in infertile patients with polycystic ovary syndrome. J Clin Endocrinol Metab. 92, 3498-3503. [Medline] [CrossRef] (Pubitemid 47435326)
10. Amin, M., Abdel-Kareem, O., Takekida, S., Moriyama, T., Abd el-Aal, G. and Maruo, T. (2003): Minireview: Up-date management of non responder to clomiphene citrate in polycystic ovary syndrome. Kobe J Med Sci. 49, 59-73. [Medline] (Pubitemid 38477600)
11. Katsiki, N., Georgiadou, E. and Hatzitolios, A. I. (2009): The role of insulin-sensitizing agents in the treatment of polycystic ovary syndrome. Drugs. 69, 1417-1431. [Medline] [CrossRef]
12. Tang, T., Lord, J. M., Norman, R. J., Yasmin, E. and Balen, A. H. (2012): Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev. 5, CD003053. [Medline]
13. Carmina, E., Chu, M. C., Longo, R. A., Rini, G. B. and Lobo, R. A. (2005): Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters. J Clin Endocrinol Metab. 90, 2545-2549. [Medline] [CrossRef] (Pubitemid 40686289)
14. Apridonidze, T., Essah, P. A., Iuorno, M. J. and Nestler, J. E. (2005): Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 90, 1929-1935. [Medline] [CrossRef] (Pubitemid 40586223)
15. Legro, R. S. (2003): Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev. 24, 302-312. [Medline] [CrossRef] (Pubitemid 36724372)
16. Rizzo, M., Berneis, K., Carmina, E. and Rini, G. B. (2008): How should we manage atherogenic dyslipidemia in women with polycystic ovary syndrome? Am J Obstet Gynecol. 198, 28 e21-25.
17. Hara, S., Takahashi, T., Amita, M., Igarashi, H. and Kurachi, H. (2010): Usefulness of bezafibrate for ovulation induction in clomiphene citrate-resistant polycystic ovary syndrome patients with dyslipidemia: a prospective pilot study of seven cases. Gynecol Obstet Invest. 70, 166-172. [Medline] [CrossRef]
18. Tenenbaum, A., Fisman, E. Z., Boyko, V., Benderly, M., Tanne, D., Haim, M., Matas, Z., Motro, M. and Behar, S. (2006): Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate. Arch Intern Med. 166, 737-741. [Medline] [CrossRef]
19. Tenenbaum, A., Motro, M., Fisman, E. Z., Schwammenthal, E., Adler, Y., Goldenberg, I., Leor, J., Boyko, V., Mandelzweig, L. and Behar, S. (2004): Peroxisome proliferatoractivated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation. 109, 2197-2202. [Medline] [CrossRef] (Pubitemid 38656105)
20. Taniguchi, A., Fukushima, M., Sakai, M., Tokuyama, K., Nagata, I., Fukunaga, A., Kishimoto, H., Doi, K., Yamashita, Y., Matsuura, T., Kitatani, N., Okumura, T., Nagasaka, S., Nakaishi, S. and Nakai, Y. (2001): Effects of bezafibrate on insulin sensitivity and insulin secretion in non-obese Japanese type 2 diabetic patients. Metabolism. 50, 477-480. [Medline] [CrossRef] (Pubitemid 32321960)
21. Tenenbaum, A., Motro, M., Fisman, E. Z., Adler, Y., Shemesh, J., Tanne, D., Leor, J., Boyko, V., Schwammenthal, E. and Behar, S. (2005): Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients. Eur Heart J. 26, 2032-2038. [Medline] [CrossRef] (Pubitemid 41435721)
22. Oktay, K., Briggs, D. and Gosden, R. G. (1997): Ontogeny of follicle-stimulating hormone receptor gene expression in isolated human ovarian follicles. J Clin Endocrinol Metab. 82, 3748-3751. [Medline] (Pubitemid 27509366)
23. Wright, C. S., Hovatta, O., Margara, R., Trew, G., Winston, R. M., Franks, S. and Hardy, K. (1999): Effects of folliclestimulating hormone and serum substitution on the in-vitro growth of human ovarian follicles. Hum Reprod. 14, 1555-1562. [Medline] [CrossRef] (Pubitemid 29265451)
24. Nayudu, P. L. and Osborn, S. M. (1992): Factors influencing the rate of preantral and antral growth of mouse ovarian follicles in vitro. J Reprod Fertil. 95, 349-362. [Medline] [CrossRef]
25. Hartshorne, G. M. (1997): In vitro culture of ovarian follicles. Rev Reprod. 2, 94-104. [Medline] [CrossRef] (Pubitemid 27271667)
26. Hara, S., Takahashi, T., Amita, M., Igarashi, H., Tsutsumi, S. and Kurachi, H. (2011): Bezafibrate restores the inhibition of FSH-induced follicular development and steroidogenesis by tumor necrosis factor-alpha through peroxisome proliferator- activated receptor-gamma pathway in an in vitro mouse preantral follicle culture. Biol Reprod. 85, 895-906. [Medline] [CrossRef]
27. Lenie, S. and Smitz, J. (2009): Functional AR signaling is evident in an in vitro mouse follicle culture bioassay that encompasses most stages of folliculogenesis. Biol Reprod. 80, 685-695. [Medline] [CrossRef]
28. Heilbronn, L. K. and Campbell, L. V. (2008): Adipose tissue macrophages, low grade inflammation and insulin resistance in human obesity. Curr Pharm Des. 14, 1225-1230. [Medline] [CrossRef] (Pubitemid 351997835)
29. Chen, X., Jia, X., Qiao, J., Guan, Y. and Kang, J. (2013): Adipokines in reproductive function: a link between obesity and polycystic ovary syndrome. J Mol Endocrinol. 50, R21-37. [Medline] [CrossRef]
30. Hotamisligil, G. S. (1999): The role of TNFalpha and TNF receptors in obesity and insulin resistance. J Intern Med. 245, 621-625. [Medline] [CrossRef] (Pubitemid 29278870)
31. Roden, M., Price, T. B., Perseghin, G., Petersen, K. F., Rothman, D. L., Cline, G. W. and Shulman, G. I. (1996): Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest. 97, 2859-2865. [Medline] [CrossRef] (Pubitemid 26197099)
32. Brown, J. E., Onyango, D. J. and Dunmore, S. J. (2007): Resistin down-regulates insulin receptor expression, and modulates cell viability in rodent pancreatic beta-cells. FEBS Lett. 581, 3273-3276. [Medline] [CrossRef] (Pubitemid 46977374)
33. Carmina, E., Orio, F., Palomba, S., Cascella, T., Longo, R. A., Colao, A. M., Lombardi, G. and Lobo, R. A. (2005): Evidence for altered adipocyte function in polycystic ovary syndrome. Eur J Endocrinol. 152, 389-394. [Medline] [CrossRef] (Pubitemid 40439491)
34. González, F. (2012): Inflammation in Polycystic Ovary Syndrome: underpinning of insulin resistance and ovarian dysfunction. Steroids. 77, 300-305. [Medline] [CrossRef]
35. Cleveland, J. L. and Ihle, J. N. (1995): Contenders in FasL/ TNF death signaling. Cell. 81, 479-482. [Medline] [Cross-Ref]
36. Hussein, M. R. (2005): Apoptosis in the ovary: molecular mechanisms. Hum Reprod Update. 11, 162-178. [Medline] [CrossRef]
37. Morrison, L. J. and Marcinkiewicz, J. L. (2002): Tumor necrosis factor alpha enhances oocyte/follicle apoptosis in the neonatal rat ovary. Biol Reprod. 66, 450-457. [Medline] [CrossRef] (Pubitemid 34101844)
38. Basini, G., Mainardi, G. L., Bussolati, S. and Tamanini, C. (2002): Steroidogenesis, proliferation and apoptosis in bovine granulosa cells: role of tumour necrosis factor-alpha and its possible signalling mechanisms. Reprod Fertil Dev. 14, 141-150. [Medline] [CrossRef]
39. Montgomery Rice, V., Limback, S. D., Roby, K. F. and Terranova, P. F. (1999): Tumor necrosis factor alpha inhibition of follicle-stimulating hormone-induced granulosa cell estradiol secretion in the human does not involve reduction of cAMP secretion but inhibition at post-cAMP site(s). Endocrine. 10, 19-23. [Medline] [CrossRef] (Pubitemid 29203580)
40. Ahmadian, M., Suh, J. M., Hah, N., Liddle, C., Atkins, A. R., Downes, M. and Evans, R. M. (2013): PPARgamma signaling and metabolism: the good, the bad and the future. Nat Med. 19, 557-566. [Medline] [CrossRef]
41. Komar, C. M., Braissant, O., Wahli, W. and Curry, T. E., Jr. (2001): Expression and localization of PPARs in the rat ovary during follicular development and the periovulatory period. Endocrinology. 142, 4831-4838. [Medline] [Cross-Ref] (Pubitemid 33022359)
42. Puttabyatappa, M., Vandevoort, C. A. and Chaffin, C. L. (2010): hCG-induced down-regulation of PPARgamma and liver X receptors promotes periovulatory progesterone synthesis by macaque granulosa cells. Endocrinology. 151, 5865-5872. [Medline] [CrossRef]
43. Kim, J., Sato, M., Li, Q., Lydon, J. P., Demayo, F. J., Bagchi, I. C. and Bagchi, M. K. (2008): Peroxisome proliferator-activated receptor gamma is a target of progesterone regulation in the preovulatory follicles and controls ovulation in mice. Mol Cell Biol. 28, 1770-1782. [Medline] [CrossRef]
44. Cui, Y., Miyoshi, K., Claudio, E., Siebenlist, U. K., Gonzalez, F. J., Flaws, J., Wagner, K. U. and Hennighausen, L. (2002): Loss of the peroxisome proliferation-activated receptor gamma (PPARgamma) does not affect mammary development and propensity for tumor formation but leads to reduced fertility. J Biol Chem. 277, 17830-17835. [Medline] [CrossRef] (Pubitemid 34967591)
45. Seto-Young, D., Avtanski, D., Strizhevsky, M., Parikh, G., Patel, P., Kaplun, J., Holcomb, K., Rosenwaks, Z. and Poretsky, L. (2007): Interactions among peroxisome proliferator activated receptor-gamma, insulin signaling pathways, and steroidogenic acute regulatory protein in human ovarian cells. J Clin Endocrinol Metab. 92, 2232-2239. [Medline] [CrossRef] (Pubitemid 46997128)
46. Hara, S., Takahashi, T., Amita, M., Matsuo, K., Igarashi, H. and Kurachi, H. (2013): Pioglitazone counteracts the tumor necrosis factor-alpha inhibition of follicle-stimulating hormone- induced follicular development and estradiol production in an in vitro mouse preantral follicle culture system. J Ovarian Res. 6, 69. [Medline] [CrossRef]